The C-Scan System

C-Scan is the first and only preparation-free test to detect precancerous polyps and enable early intervention and cancer prevention.

More than one third of the U.S. screening age population avoids standard screening procedures such as colonoscopy. C-Scan has the potential to offer a more patient-friendly option, enabling people to get the screening they need.

No bowel preparation
No sedation, pain or discomfort
No interruption of daily routine
Cloud based analysis suite allows physicians to analyze data anywhere
No operating room needed at the hospital to perform the screening

How does C-Scan work?

Once the ingestible capsule C-Scan Cap is swallowed, it travels naturally along the gastrointestinal tract while scanning the inner lining of the colon. C-Scan Cap actively communicates with the second element of the system, C-Scan Track, which records and stores the scanning data. When the screening procedure is over, C-Scan Cap will be excreted naturally, the patient is notified, and the scanning data can be analyzed by using our proprietary software, C-Scan View.

C-Scan Cap

  • Ingestible capsule
  • Emission of ultra-low dose X-ray beams
  • Scanning of gastrointestinal tract
  • Autonomous and natural passage through the gastrointestinal tract
  • Total X-ray exposure dose similar to that of a single chest radiography

C-Scan Track

  • Three miniaturized patches worn on the patient’s back
  • Integrated positioning, control and recording system
  • Continuous recording and storage of C-Scan Cap’s information

C-Scan View

  • Cloud based analysis suite allows physicians to analyze data anywhere
  • Construction of maps of the inner surface of the colon
  • Pre-analysis and bookmarking of suspicious findings by an expert technician

The C-Scan’s technology is based on two physical phenomena related to the interaction of the X-ray photons emitted by the capsule with the contents of the colon and the tissue wall.

The first is X-ray fluorescence: When X-ray photons interact with the ingested contrast agent that mixes with the colon content, secondary X-ray fluorescence photons are generated, some of which are back scattered and detected by the x-ray detectors in the capsule.

The second phenomenon is Compton scattering: When emitted X-ray photons interact with electrons of atoms in the colon wall and lumen some of the photons scattered by this mechanism head back in the direction of the capsule with an energy correlated to their angle of scatter.

The number of detected X-ray fluorescence photons and Compton back-scattered photons is correlated to the distance between the capsule and the colon wall. As the distance between the capsule and the colon wall increases, presence of content induces higher rates of X-ray fluorescence photons. At the same time, the content attenuates Compton back-scattered photons, hence decreasing the corresponding detection rate.

The close proximity of the capsule to the scanning target allows for the use of an ultra-low dose radiation, since a very low x-ray flux is required to obtain sufficient signal-to-noise ratio and good scanning quality.


Clinical Study Results For C-Scan in Israel and the EU

In a multi-center, open label prospective study performed in Israel, the C-Scan System demonstrated high sensitivity and specificity for the detection of precancerous polyps when compared to FIT (fecal immunochemical test), a commonly used non-invasive colorectal cancer screening test. Colonoscopy was used as the reference method.

  • Sensitivity – ability to correctly identify patients with polyps
  • Specificity – ability to correctly identify patients with lack of polyps

U.S. Pilot Trial Results

Check-Cap completed a pilot study in the U.S. to evaluate the safety, usability and subject compliance of the C-Scan® system. The study was conducted at two sites, the New York University Grossman School of Medicine and Mayo Clinic.

  • Positive results were reported from 28 evaluable study subjects (out of 40 who completed the study).
  • The primary endpoint was achieved, and no device or procedure related serious adverse events were reported.
  • All patients who underwent the study complied with the procedure and completed a questionnaire after the test, reporting higher satisfaction with the C-Scan System compared to colonoscopy.
  • The study also showed an agreement between C-Scan and colonoscopy in detection of polyps for evaluable patients, consistent with data from the post-CE approval study*.

*Due to sample size, the study was not designed to be powered for statistical significance

Regulatory approvals

The C-Scan® system has received CE mark in Europe and approval from the Israeli Ministry of Health, the Medical Device Division (AMAR), for marketing in Europe and Israel, respectivelly.

Publications & Presentations/Events

The C-Scan System is not approved in the United States and is currently an investigational device there.
The system is approved in the E.U. and Israel but it is not available for sale in any jurisdiction.
This website is not intended to provide medical advice for patients or healthcare providers.

Skip to content